CoChat

Rifaximin versus chlortetracycline in the short‐term treatment of small intestinal bacterial overgrowth

Open access
Di Stefano, Malservisi, Veneto, Ferrieri, Corazza · 2000 · Alimentary Pharmacology & Therapeutics
Cited by 154

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Bacterial overgrowth of the small intestine is a condition characterized by nutrient malabsorption due to an excessive number of bacteria in the lumen of the small intestine. Current treatment is based on empirical courses of broad spectrum antibiotics; few controlled data, with respect to the duration and choice of antibiotic drug, exist at present. The recent availability of rifaximin, a non‐absorbable rifamycin derivative, highly effective against anaerobic bacteria, prompted us to carry out a randomized, double‐blind controlled trial in order to compare its efficacy and tolerability to those of tetracycline, currently considered the first‐choice drug. Methods: In 21 patients affected by small intestinal bacterial overgrowth, fasting, peak and total H 2 excretion after ingestion of 50 g glucose and severity of symptoms were evaluated before and after a 7‐day course of rifaximin, 1200 mg/day (400 mg t.d.s.), or chlortetracycline, 1 g/day (333 mg␣t.d.s.). Results: Fasting, peak and total H 2 excretion decreased significantly in the group of patients treated with rifaximin whereas chlortetracycline did not modify these parameters. The H 2 breath test normalized in 70% of patients after rifaximin and in 27% of patients after chlortetracycline. The improvement in symptoms was significantly higher in patients treated with rifaximin. Conclusions: Rifaximin is a promising, easily‐handled and safe drug for the short‐term treatment of small intestinal bacterial overgrowth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00751.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 154

Metadata

Authors
Stefano, D., Malservisi, Veneto, Ferrieri, & Corazza
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2000-05
Volume
14
Issue
5
Pages
551-556
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2091756720
Cited by
154
References
1
FWCI
2.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.